Literature DB >> 6191211

Characterization of a new, short-acting and specific inhibitor of type A monoamine oxidase.

P C Waldmeier, P A Baumann, A Delini-Stula, R Bernasconi, K Sigg, O Buech, A E Felner.   

Abstract

Mesh：

Substances：

Year:  1983        PMID： 6191211     DOI： 10.1159/000407502

Source DB:  PubMed          Journal:  Mod Probl Pharmacopsychiatry        ISSN： 0077-0094


× No keyword cloud information.
  7 in total

1.  Effects of brofaremine (CGP 11 305A), a short-acting, reversible, and selective inhibitor of MAO-A on sleep, nocturnal penile tumescence and nocturnal hormonal secretion in three healthy volunteers.

Authors:  A Steiger; F Holsboer; O Benkert
Journal:  Psychopharmacology (Berl)       Date:  1987       Impact factor: 4.530

Review 2.  Brofaromine--a review of its pharmacological properties and therapeutic use.

Authors:  H P Volz; C H Gleiter; P C Waldmeier; M Struck; H J Möller
Journal:  J Neural Transm (Vienna)       Date:  1996       Impact factor: 3.575

3.  In vivo evidence for the reversible action of the monoamine oxidase inhibitor brofaromine on 5-hydroxytryptamine release in rat brain.

Authors:  N Bel; F Artigas
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1995-05       Impact factor: 3.000

4.  Phenylethylamine-induced stereotypies in the rat: a behavioral test system for assessment of MAO-B inhibitors.

Authors:  R Ortmann; M Schaub; A Felner; J Lauber; P Christen; P C Waldmeier
Journal:  Psychopharmacology (Berl)       Date:  1984       Impact factor: 4.530

5.  Urinary excretion of O-methylated catecholamines, tyramine and phenyl-ethylamine by volunteers treated with tranylcypromine and CGP 11305 A.

Authors:  P C Waldmeier; K H Antonin; J J Feldtrauer; C Grunenwald; E Paul; J Lauber; P Bieck
Journal:  Eur J Clin Pharmacol       Date:  1983       Impact factor: 2.953

6.  Effects of CGP 11305 A, a new reversible and selective inhibitor of MAO A, on biogenic amine levels and metabolism in the rat brain.

Authors:  P C Waldmeier; P A Baumann
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1983-09       Impact factor: 3.000

Review 7.  Pharmacokinetic optimisation of therapy with newer antidepressants.

Authors:  P J Goodnick
Journal:  Clin Pharmacokinet       Date:  1994-10       Impact factor: 6.447
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.